Lynch M, Pentecost B L, Littler W A, Stockley R A
General Hospital, Birmingham, United Kingdom.
Am J Cardiol. 1994 Nov 1;74(9):849-52. doi: 10.1016/0002-9149(94)90574-6.
The aims of this study were (1) to assess the possibility of predicting allergic reactions to streptokinase (SK) by measuring pretreatment antibody titers and by intradermal skin testing, and (2) to determine if SK is associated with subclinical changes in renal function. Specific anti-SK immunoglobulin G (IgG) and subclass IgG1 were assessed by enzyme-linked immunosorbent sorbent assays, and renal function was assessed by measurement of serum urea and creatinine in 204 patients with acute myocardial infarction. Twenty-six patients had 24-hour proteinuria loss and creatinine clearance assessed at presentation. Median IgG titer at presentation was 6 (range 0 to 10,000), and increased to 60 (range 0 to 18,000; p < 0.0001) on day 6. Fifteen of 180 patients (8.3%) had minor allergic reactions to SK; the median titer on admission for these patients was 5 (range 0 to 60), identical to those who tolerated SK uneventfully. No change was seen in serum urea or creatinine; for those treated with SK, the median value for proteinuria loss at day 0 was 0.45 g/liter (range 0.1 to 2), and decreased by day 5 to 0.1 g/liter (range 0.1 to 0.8; p = 0.0027). No significant proteinuria was seen in those who did not receive SK. The reactions to SK were minor, and could not be predicted on the basis of IgG titers at presentation. Significant proteinuria was found in the first 24 hours in SK-treated patients, but not in those who did not receive SK, and it resolved by day 5.
(1)通过测量治疗前抗体滴度和进行皮内皮肤试验来评估预测对链激酶(SK)过敏反应的可能性;(2)确定SK是否与肾功能的亚临床变化相关。通过酶联免疫吸附测定法评估特异性抗SK免疫球蛋白G(IgG)和IgG1亚类,通过测量204例急性心肌梗死患者的血清尿素和肌酐来评估肾功能。26例患者在就诊时评估了24小时蛋白尿丢失和肌酐清除率。就诊时IgG滴度中位数为6(范围0至10,000),第6天时升至60(范围0至18,000;p<0.0001)。180例患者中有15例(8.3%)对SK有轻微过敏反应;这些患者入院时的滴度中位数为5(范围0至60),与顺利耐受SK的患者相同。血清尿素或肌酐未见变化;接受SK治疗的患者,第0天蛋白尿丢失的中位数为0.45 g/升(范围0.1至2),到第5天时降至0.1 g/升(范围0.1至0.8;p = 0.0027)。未接受SK治疗的患者未见明显蛋白尿。对SK的反应轻微,无法根据就诊时的IgG滴度进行预测。SK治疗的患者在最初24小时内出现明显蛋白尿,但未接受SK治疗的患者未出现,且在第5天时消失。